Remove Marketing Remove Pharma Companies Remove Trials
article thumbnail

Is biotech facing a long bear market?

Pharmaceutical Technology

Talks of a bear market in the biotech sector do not seem to pass, with news of companies falling into administration and layoffs becoming a recurrence. Other businesses such as Redhill Biopharma or Vincerx Pharma have also announced plans for large layoffs. This is particularly felt among smaller retail investors.

Marketing 324
article thumbnail

Takeda discontinuing in AAV and rare haematology disease markets

Pharmaceutical Technology

Takeda’s announcement underlines the risk associated with gene therapy R&D at the preclinical stage and the fact that many current AAV programs are unlikely to reach late-stage trials. Takeda’s pivot away from AAV gene therapy follows a similar action taken by Pfizer in January 2023 to externalise its gene therapy R&D.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Brazil: untapped market for big pharma manufacturing

Pharmaceutical Technology

International companies investing in the emerging market of Brazilian pharmaceutical manufacturing will see a higher return on investment than from developed market equivalents, if they choose to compete with local manufacturers to supply Brazil’s growing market and the greater South American region.

article thumbnail

Jupiter Neurosciences Makes Way in CNS Treatments with $11M IPO

XTalks

Jupiter Neurosciences, a clinical-stage pharma company specializing in neuroinflammation, made its public market debut with an initial public offering (IPO) on the Nasdaq Capital Market under the symbol “JUNS.” ” The company priced 2,750,000 shares of common stock at $4.00

article thumbnail

HCPs are overwhelmed by promotional content in digital

World of DTC Marketing

As HCPs get more digitally savvy, pharma marketers should understand that engaging physicians through channels and time of their preference with content relevant to the individual customer. is no more an option but a critical factor to ensure success for any multichannel marketing initiatives.

article thumbnail

Your HCP marketing just became harder, a lot harder

World of DTC Marketing

Yet many other agents that clear amyloid have ultimately been found ineffective in clinical trials , and for a while, it looked like aducanumab would have a similar fate. Then Biogen reported that the drug had worked in the high-dose arm of one of its late-stage trials. appeared first on World of DTC Marketing.com.

Marketing 187
article thumbnail

HCP’s use of social media: the good and the not so good

World of DTC Marketing

86% of diagnostic device companies, 65% of pharma marketers, and over half of biotechs use social as a critical part of their marketing mix to reach HCPs. HCPs don’t necessarily want pharma trying to sell products via social media. Doximity was flagged for having anti-vaccine information.

Nurses 294